Linaclotide NEW
| Price | $45 | $106 | $197 |
| Package | 1mg | 5mg | 10mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-09 |
Product Details
| Product Name: Linaclotide | CAS No.: 851199-59-2 |
| Purity: 98.94% | Supply Ability: 10g |
| Release date: 2026/06/09 |
Product Introduction
Bioactivity
| Name | Linaclotide |
| Description | Linaclotide, developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, is a potent and selective guanylate cyclase C agonist. |
| In vitro | Linaclotide acts on guanylate cyclase-C receptors on the luminal membrane to increase chloride and bicarbonate secretions into the intestine, inhibit sodium ion absorption, enhance water secretion into the lumen, and improve defecation; the drug is minimally absorbed into the systemic circulation[2]. In vitro, linaclotide inhibits [125I]-STa binding to intestinal mucosal membranes from wt mice in a concentration-dependent manner, while binding to membranes from GC-C null mice significantly decreases. Linaclotide is completely degraded after a 30-minute incubation in jejunal fluid in vitro[1]. |
| In vivo | Linaclotide significantly increases weekly spontaneous bowel movements and complete spontaneous bowel movements (CSBMs) while reducing abdominal pain in patients with chronic constipation [2]. Pharmacokinetic analysis shows very low oral bioavailability (0.10%). In intestinal secretion and transit models, linaclotide exhibits significant pharmacological effects in wt, but not in GC-C null mice: increased fluid secretion into surgically ligated jejunal loops is accompanied by elevated cyclic guanosine-3',5-monophosphate levels and accelerated gastrointestinal transit [1]. |
| Storage | Keep away from moisture Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 20 mg/mL (13.1 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (6.55 mM), Suspension. 10% DMSO+90% Saline : < 10 mg/mL (6.55 mM), Lower concentrations may be soluble, but exact solubility limit is unknown. DMSO : 150 mg/mL (98.25 mM) |
| Keywords | Linaclotide | Inhibitor | inhibit | Guanylatecyclase | Guanylate Cyclase |
| Inhibitors Related | LY83583 | Lificiguat | Sinitrodil | NPR-C activator 1 | Riociguat | Nelociguat | Nitroprusside disodium dihydrate | NS-2028 | Indusatumab | Methylene Blue | Methylene Blue trihydrate | Cinaciguat |
| Related Compound Libraries | Bioactive Compound Library | Cyclic Peptide Library | Membrane Protein-targeted Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Peptide Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
|
VIP5Y
|
Sinoway Industrial co., ltd.
|
2026-06-22 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-22 | ||
| $1000.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-22 | |
|
VIP2Y
|
Watson Biotechnology Co.,Ltd
|
2026-06-17 | ||
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-16 | ||
|
VIP3Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2026-06-12 | ||
| $45.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-09 | |
|
VIP1Y
|
Jinan Ruitong Biotech Co., Ltd.
|
2026-06-08 | ||
| $1000.00 |
VIP1Y
|
Chengdu Shengnuo Biopharm Co.,Ltd
|
2026-05-28 | |
| $2270.00 |
VIP6Y
|
Baoji Guokang Healthchem Co., Ltd.
|
2026-05-15 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY